A Future Perspective on the Involvement of <i>n</i>-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

DOI Web Site Web Site PubMed 41 References
  • Nakamoto Kazuo
    Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University
  • Obata Tokio
    Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University
  • Hirasawa Akira
    Department of Genomic Drug Discovery Science, Graduate School of Pharmaceutical Sciences, Kyoto University
  • Ih Kim Ke
    Department of Pharmacy, Kobe Asahi Hospital
  • Ryang Kim Soo
    Department of Gastroenterology, Kobe Asahi Hospital
  • Tokuyama Shogo
    Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Kobe Gakuin University

Bibliographic Information

Other Title
  • NAFLD/NASH発症における<i>n</i>-3系多価不飽和脂肪酸の関与と将来展望
  • Symposium Review NAFLD/NASH発症におけるn-3系多価不飽和脂肪酸の関与と将来展望
  • Symposium Review NAFLD/NASH ハッショウ ニ オケル n-3ケイ タカ フホウワ シボウサン ノ カンヨ ト ショウライ テンボウ

Search this article

Abstract

 Nonalcoholic fatty liver disease (NAFLD) is characterized by the pathological accumulation of fat in the liver in the absence of any other disease related to liver steatosis, which includes a wide spectrum of liver diseases ranging from mild asymptomatic fatty liver to nonalcoholic steatohepatitis (NASH) and cirrhosis. Recently, it was reported that NAFLD is characterized by the impaired bioavailability of liver n-6 and n-3 long-chain polyunsaturated fatty acids (PUFAs). That is, compared with healthy individuals, steatosis and steatohepatitis patients have higher n-6/n-3 PUFA ratios. Furthermore, per recent research, decreasing the intake of total fats and increasing the intake of n-3 PUFAs may be beneficial in the treatment of NAFLD. In contrast, some reports describe that NASH patients have more metabolic abnormalities than NAFLD patients; however, these are not influenced by dietary fatty acids. Thus, at present, various opinions exist regarding the efficacy of n-3 PUFA in the treatment of NAFLD. In this review, we discuss the considerable interest n-3 PUFA has attracted as a potential treatment for NAFLD.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 136 (4), 583-589, 2016-04-01

    The Pharmaceutical Society of Japan

References(41)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top